StockNews.AI
LGND
StockNews.AI
117 days

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

1. LGND will report Q1 2025 results on May 8, 2025. 2. A conference call will update stakeholders on financial performance. 3. Ligand focuses on mid- to late-stage drug development financing. 4. They operate unique technologies—Captisol® and NITRICIL™ for drug enhancement. 5. LGND maintains partnerships with major pharma companies for drug commercialization.

Earnings
+0.99%Current Return
VS
+2.13%S&P 500
$105.7604/24 07:14 AM EDTEvent Start
$106.80504/25 01:56 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report typically drives interest and can uplift stock prices, especially in biotech.

How important is it?

Earnings events can significantly influence stock valuations; market sentiment is currently favorable.

Why Short Term?

Results are imminent, and investor sentiment may shift as the date approaches.

Related Companies

AMGNMRKPFEGILD
April 24, 2025 07:00 ET  | Source: Ligand Pharmaceuticals JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. ContactsInvestors:Melanie Hermaninvestors@ligand.com(858) 550-7761 Media:         Kellie Walshmedia@ligand.com(914) 315-6072

Related News